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Abstract
Background: The causes of increased cardiovascular risk in systemic lupus erythematosus (SLE) are not understood
thoroughly, although presence of traditional cardiovascular risk factors and disease-specific agents were also
proposed. In this study, we investigated the quantitative changes in the lipid profile, as well as qualitative
characteristics of high-density lipoprotein (HDL) and markers of inflammation and disease activity in SLE patients.
Methods: Lipoprotein levels were determined in 51 SLE patients and 49 healthy controls, matched in age and
gender. HDL antioxidant capacity was determined spectrophotometrically with a cell-free method of hemin-
induced low-density lipoprotein (LDL) oxidation. Polyacrylamide gel-electrophoresis was used for HDL subfraction
analysis. Human paraoxonase-1 (PON1) activity, apolipoprotein A1 (ApoA1) and oxidized LDL concentrations, as well
as interleukin-6, high-sensitivity C-reactive protein, serum amyloid A and monocyte chemotactic protein-1 levels
were determined.
Results: HDL-cholesterol and ApoA1 concentrations decreased significantly in SLE subjects. Also, PON1 arylesterase
activity (125.65 ± 26.87 vs. 148.35 ± 39.34 U/L, p = 0.001) and total HDL antioxidant capacity (165.82 ± 58.28 % vs.
217.71 ± 54.36 %, p < 0.001) were significantly reduced in patients compared to controls. Additionally, all HDL
subfraction concentrations were significantly decreased in patients, while the levels of the examined inflammatory
markers were significantly elevated in SLE subjects. The latter correlated positively with disease activity, and
negatively with HDL concentration and total HDL antioxidant capacity, respectively. PON1 arylesterase activity and
erythrocyte sedimentation rate were independent predictors of total HDL antioxidant capacity.
Conclusions: Induced by the systemic inflammation, altered composition and antioxidant activity may diminish the
anti-atherogenic effect of HDL and therefore may contribute to the increased cardiovascular risk of SLE patients.
Keywords: HDL antioxidant capacity, paraoxonase-1, HDL subfractions, SLE, oxidized LDL, cardiovascular disease
Background
Several investigations attempted to clarify the back-
ground of increased cardiovascular (CV) morbidity and
mortality in systemic lupus erythematosus (SLE), which
is one of the most common systemic autoimmune
diseases [1]. SLE patients suffer from accelerated athero-
sclerosis, featured by increased carotid intima-media
thickness (cIMT), carotid plaques and endothelial
dysfunction, as well as impaired flow-mediated dilation
(FMD) in the brachial artery [2]. Higher prevalence of
traditional cardiovascular risk factors and disease specific
agents were also suggested to play a role in the course of
plaque formation.
Previous studies reported the “lupus pattern” of lipopro-
teins in SLE that is characterized by elevated triglyceride
(TG) and very-low-density lipoprotein (VLDL) concentra-
tions together with decreased high-density lipoprotein
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cholesterol (HDL) levels, usually occurring in the active
phases of the disease [3, 4]. Others reported increased
low-density lipoprotein (LDL) and total cholesterol
(TC) concentrations during the periods of lower disease
activity [3, 5].
Inflammation is a key factor both in SLE and athero-
sclerosis. During acute or chronic inflammation, HDL
suffers substantial changes both in composition and
function, diminishing its anti-atherogenic effects. The
concentration of apolipoprotein A1 (ApoA1), which is
the main structural protein of HDL, decreases during
the acute phase response. Also, myeloperoxidase-
dependent chlorination of ApoA1 side-chains impairs
the ability of HDL to facilitate reverse cholesterol trans-
port (RCT) via the ATP-binding cassette transporter A1
(ABCA1) pathway [6]. Previous data suggest that the
direct anti-oxidant effect of HDL on LDL oxidation,
measured as a reduction in lipid peroxides, is likely
mediated by HDL-linked paraoxonase-1 (PON1) [7, 8].
This major antioxidant effect might be mitigated in
inflammatory conditions. Qualitative changes of the
HDL reported in inflammatory states are partly the
direct results of altered gene expression of HDL-
associated proteins including serum amyloid A that is
modulated by inflammatory cytokines. Furthermore,
altered lipoprotein metabolism may indirectly influence
the composition and function of HDL. Both of these
mechanisms may be responsible for the decrease in the
ApoA1 levels. Reverse cholesterol transport is also
impaired during acute phase reaction [9].
Indeed, diminished PON1 activity was reported in SLE
patients compared to healthy controls [10]. Incorpor-
ation of serum amyloid A (SAA) into the HDL particle
results in a structural modification of the lipoprotein
with a consequent functional deficiency, characterized
by reduced inhibition of monocyte chemoattractant
protein-1 (MCP-1) production in vascular smooth
muscle cells [11]. High levels of acute phase reactant
C-reactive protein (CRP), SAA and increased erythrocyte
sedimentation rate (ESR) were described previously in SLE
patients together with elevated MCP-1 and interleukin-6
(IL-6) concentrations, which showed positive associations
with coronary calcification [12, 13].
By now, just a few studies analyzed the distribution of
the HDL subfractions in SLE and the results are contro-
versial. Regardless their history of cardiovascular disease,
small HDL subfractions (sHDL) were found to be less
prevalent in SLE patients than in healthy controls [14].
Moreover, in a cohort of 69 SLE patients, sHDL particles
were in direct correlation with cIMT, C3, C4 and CH50
complement levels [15].
A cell-free method was developed by Navab et al. to
determine the inhibitory effect of HDL on LDL oxida-
tion [16]. Proinflammatory HDL (piHDL) was detected
if the fluorescent signal generated upon oxidation turned
out to be larger in the joint presence of HDL and LDL,
than LDL alone. It was reported that almost half of the
SLE patients have piHDL (44.7 % vs. 4.1 % in healthy
controls), with increasing prevalence further up to
86.7 % in those with concurrent carotid plaque [17, 18].
In SLE patients, the prevalence of piHDL correlated with
the occurrence of carotid plaque and cardiovascular
complications and also with the concentrations of
oxidized LDL (oxLDL) [17, 18].
Using hemin as a physiological pro-oxidant, we also
developed a cell-free method to assess the antioxidant
capacity of HDL [19]. Data were suitable for multiplication
with HDL concentration, resulting total HDL antioxidant
capacity, which is able to characterize antioxidant attribute
and concentration of HDL simultaneously.
This study of SLE patients and healthy controls was
organized to compare HDL antioxidant capacities by the
cell-free method of hemin-induced LDL oxidation and to
compare lipoprotein and ApoA1 concentrations, PON1
activities and HDL subfractions. To get a more complex
picture on the relationship between inflammation and
lipids in SLE, associations between inflammatory markers
and lipid parameters were also examined.
Methods
Study population
51 patients with SLE and 49 healthy controls were
enrolled. Patients were treated in the Division of Clinical
Immunology, Department of Medicine, University of
Debrecen. All patients fulfilled at least four of the revised
American College of Rheumatology (ACR) classification
criteria for SLE [20]. Controls were recruited from health
care professionals and healthy local habitants. Subjects
with renal failure (GFR < 60 ml/min/1,73 m2), diabetes
mellitus or statin use were excluded due to their impact
on HDL anti-inflammatory function [21, 22]. Patients and
controls were matched in age, gender and smoking habits,
for those affect lipid profile and HDL antioxidant enzyme
activities [23, 24]. The study was approved by the Ethical
Committee of University of Debrecen and all participants
gave written informed consent.
Clinical data on age, gender, smoking habits, statin
intake, hypertension (use of antihypertensive medica-
tion or blood pressure ≥ 140/90 mmHg), diabetes
mellitus (use of antidiabetic medication or fasting
blood glucose ≥ 7 mmol/L or postprandial blood
glucose ≥11.1 mmol/L), previous cerebrovascular or
cardiovascular disease (transient ischemic attack, ischemic
or hemorrhagic stroke, myocardial infarct or angina
pectoris) were collected in both study groups. Disease
activity was assessed by the SLEDAI score [25] and disease
duration, disease manifestations as well as current therapy
were also recorded.
Gaál et al. Lipids in Health and Disease  (2016) 15:60 Page 2 of 8
Among the 51 patients, 42 used methylprednisolon, 20
azathioprine, 11 chloroquine and 2 cyclosporine A.
Average daily steroid dose was 4 mg, ranging from 0 to
32 mg; while 5 patients did not take any drugs at the
time of blood sampling.
Sample collection and laboratory measurements
Venous blood samples were collected after a 12-h fast.
Routine laboratory parameters, including blood counts,
glucose level, ESR, renal and hepatic function tests were
determined from fresh sera with a Cobas c501 analyzer
(Roche Ltd, Mannheim, Germany). High-sensitivity C-
reactive protein (hsCRP), ApoA1, apolipoprotein B
(ApoB) and lipoprotein (a) [Lp(a)] concentrations were
assessed by immunoturbidimetric assays. Total cholesterol
(TC), triglyceride (TG), high-density lipoprotein choles-
terol (HDL-C) and low-density lipoprotein cholesterol
(LDL-C) levels were measured by enzymatic colorimetric
tests (Modular P-800 Analyzer, Roche/Hitachi). Autoanti-
bodies specific for SLE and antiphospholipid syndrome
(a-dsDNA, a-Sm, a-SSA, a-SSB; a-CL IgA, a-CL IgG,
a-CL IgM, a-B2 IgA, a-B2 IgG, a-B2 IgM), immunoglobu-
lin (IgA, IgG, IgM), complement (C3, C4) and immune
complex concentrations were tested with commercially
available enzyme-linked immunosorbent assay (ELISA)
kits. Cytokines, acute phase markers and oxLDL were
tested with commercially available ELISA assays (IL-6:
R&D Systems Inc., Minneapolis, USA; serum amyloid A
(SAA): Antigenix America Inc., NY, US; MCP-1: R&D
Systems Inc., Minneapolis, USA; oxLDL: Biomedica,
Vienna, Austria). Assays were performed according to the
recommendations of the manufacturers.
Determination of HDL antioxidant capacity
Our method to determine HDL antioxidant capacity has
been described previously [19]. The effect of HDL was
measured by heme-catalyzed oxidation of LDL in the
absence and presence of HDL. Using HDL samples of
identical cholesterol concentrations, the inhibitory effect
of HDL on LDL oxidation (termed specific HDL antioxi-
dant capacity) was assessed by measuring ΔTVmax of
hemin-catalyzed LDL oxidation in the absence and pres-
ence of HDL. HDL was isolated from sera with density
gradient ultracentrifugation and hydrogen peroxide was
used to split the heme ring and release redox-active iron
in order to accelerate the reaction. LDL oxidation was
followed spectrophotometrically by measuring hemin
degradation. The HDL antioxidant capacity was expressed
as the percentage ratio of ΔTVmax in the presence and
absence of HDL [19, 26].
Total HDL antioxidant capacity values were calcu-
lated by multiplying the specific HDL antioxidant
capacity values with the HDL concentrations of the
study participants.
Determination of human paraoxonase-1 enzyme activities
and phenotype distribution
PON1 paraoxonase activity was analyzed on a microtiter
plate by a kinetic, semiautomated method using paraoxon
(O,O-diethyl-O-p-nitrophenyl-phosphate, Sigma Aldrich,
Hungary) as a substrate. PON1 arylesterase activity was
assayed with a phenylacetate substrate (Sigma Aldrich,
Hungary) and the hydrolysis of phenylacetate was moni-
tored at 270 nm [10] The dual substrate method was used
to determine the phenotypic distribution of PON1, (ratio
of salt-stimulated paraoxonase to the hydrolysis of phenyl
acetate): ratio < 3.0 for AA, ratio between 3.0 and 7 for AB
and ratio >7.0 for BB phenotype.
HDL subfraction analysis
HDL subfractions were detected by an electrophoretic
method on polyacrylamide gel with the Lipoprint System
(Quantimetrix Corp., CA, USA) according to manufac-
turer’s instructions. Lipoprint separates HDL subfrac-
tions from human serum on the basis of their size
applying preloaded gel tubes for HDL determinations.
Samples from 51 SLE patients and from 40 controls
were analyzed.
Concisely, 25 μl serum was added to the polyacrylamide
gel tubes along with 300 μl loading gel solution. The tubes
contained Sudan Black as a lipophilic dye and were
photopolimerized at room temperature for 30 min.
Electrophoresis with tubes containing sera samples or
the manufacturer’s quality controls was performed at
a constant of 3 mA/tube for 50 min. Subfraction bands
were scanned with an ArtixScan M1 digital scanner
(Microtek International Inc., CA, USA) and were
identified by their mobility (Rf ) using VLDL as the
starting (Rf 0°0) and albumin as the ending (Rf 1°0)
reference point.
Ten HDL subfractions were differentiated between LDL
and albumin peaks, and were grouped into three major
classes: large (from HDL1 to HDL3), intermediate (from
HDL4 to HDL7) and small (HDL8 to HDL10) HDL
subfractions. Cholesterol concentrations of the HDL
particle subsets were calculated by multiplying the total
cholesterol concentration of the samples by the relative
area under the curve (AUC) of the subfraction bands.
Statistical analysis
The normality of continuous variables was assessed by
the Kolmogorov-Smirnov test. Normally distributed data
were expressed as mean (±SD), while data not normally
distributed were expressed as median (interquartile
range [IQR]). Continuous variables were compared by
Student’s t-test or Mann–Whitney U test, as appropriate.
Associations between continuous variables were assessed
by Pearson’s or Spearman’s correlation coefficient, de-
pending on the normality of data. Multiple regression
Gaál et al. Lipids in Health and Disease  (2016) 15:60 Page 3 of 8
analysis (backward-stepwise method) was performed to
determine variables best predicted the total HDL antioxi-
dant activity. The level of significance was set at P < 0.05.
Analyses were performed on Statistica – Version 8
computer software (StatSoft Inc.).
Results
Basic characteristics and lipid profile
Basic clinical and laboratory characteristics including
lipoprotein concentrations of the study groups are
presented in Table 1. SLE patients were relatively
young with a mean disease duration of 6.59 ± 5.26 years
and their SLEDAI score was 4.0 [2.0 – 6.0], ranging from
0 to 38. Although the glucose level was significantly higher
in SLE patients compared to controls, it was still in the
normal range. Significantly lower HDL and ApoA1 levels,
as well as significantly higher triglyceride and ApoB100
levels were found in SLE patients compared to controls.
Antioxidant capacity and PON1 phenotype distribution
Compared to controls, SLE patients displayed non-
significantly decreased PON1 paraoxonase and signifi-
cantly decreased PON1 arylesterase activities (Table 2).
To assess whether altered PON1 activity was due to the
decreased HDL level found in SLE group, we standard-
ized the enzyme activity for the HDL concentration
(PON1/HDL ratio). We found that the standardized
enzyme activities were significantly higher in the SLE
patients compared to controls. Additionally, significantly
lower (−23.83 %) total HDL antioxidant, while slightly,
but significantly higher (3.72 %) specific HDL antioxi-
dant capacities were found in the SLE patients.
The PON1 AA phenotype, indicating the lowest PON1
enzyme activity was present in 94 % of the SLE patients
and 87.23 % of controls. AB phenotype with intermedi-
ate enzyme activity was found in 6 % of the patients vs.
12.77 % of the controls. BB phenotype, the indicator of
the highest PON1 enzyme activity, was not present in ei-
ther of the study groups. Allele B of PON1 associated
with higher enzyme activity was twice as frequent in
healthy subjects vs. SLE patients (6.38 % vs. 3 %).
Inflammatory markers including hsCRP levels and ESR
were significantly increased in the SLE patients. Also,
concentrations of IL-6, MCP-1 and SAA were found to
be significantly increased in the patient group.
HDL subfraction analysis
Compared to the control individuals, Lipoprint analysis
of the sera showed uniformly and significantly lower
amounts of the HDL fractions in the SLE patients
(Table 3). However, there were no significant differences
in the distribution of the HDL subfractions between the
two groups.
Correlations between markers of oxidative stress and
inflammation
Both HDL-C and total HDL antioxidant capacity corre-
lated positively with PON1 arylesterase (Fig. 1) and para-
oxonase activity in SLE patients, but not in controls.
HDL-C and total HDL antioxidant capacity showed
significant negative correlations with the inflammatory
Table 1 Basic clinical and laboratory characteristics of the study groups
Characteristics SLE patients (n = 51) Controls (n = 49) P Value
Gender (female/male) 44/7 41/8 0.717
Age (yr) 31.82 ± 6.40 31.8 ± 6.81 0.983
BMI (kg/m2) 24.45 ± 4.13 23.86 ± 4.28 0.489
Current smoker (%) 31.37 26.53 0.484
Systolic blood pressure (mmHg) 115 (110–120) 117 (110–120) 0.952
Diastolic blood pressure (mmHg) 70 (70–80) 78 (70–80) 0.592
Glucose (mmol/L) 4.89 ± 0.77 4.32 ± 0.57 <0.001
Total cholesterol (mmol/L) 4.57 ± 1.12 4.81 ± 0.80 0.222
LDL-cholesterol (mmol/L) 2.60 ± 0.84 2.71 ± 0.69 0.473
HDL-cholesterol (mmol/L) 1.26 ± 0.47 1.71 ± 0.45 <0.001
Non-HDL cholesterol (mmol/L) 3.22 ± 1.23 3.10 ± 0.78 0.573
Triglycerides (mmol/L) 1.25 (0.9-1.9) 0.90 (0.7-1.4) 0.005
Apolipoprotein A1 (g/l) 1.39 ± 0.35 1.66 ± 0.41 <0.001
Apolipoprotein B-100 (g/l) 0.86 ± 0.26 0.76 ± 0.22 0.047
Lipoprotein (a) (mg/l) 106 (29–294) 76 (29–169) 0.240
ApoA1/HDL (g/mmol) 1.17 ± 0.26 0.99 ± 0.17 <0.001
Statistically significant differences are marked in bold
Gaál et al. Lipids in Health and Disease  (2016) 15:60 Page 4 of 8
markers including ESR (Fig. 2), hsCRP, IL-6, MCP-1, and
SAA (Table 4). HDL antioxidant capacity showed a
significant inverse relationship with immune complex
level (Fig. 3); however, we could not find significant
correlations between disease activity index and
ApoA1, HDL-C or total HDL antioxidant capacity
(data not shown).
In the SLE patients, PON1 paraoxonase activity
correlated positively with the proportion of large HDL
% (r = 0.34808, P = 0.0123) and with its concentration
(r = 0.33598, P = 0.0159), while it showed a negative
association with the proportion of intermediate HDL
(r = −0.38145, P = 0.0057). In the controls, PON1
paraoxonase and arylesterase activities correlated only
with the concentration of the intermediate HDL (data
not shown). PON1 arylesterase activity showed posi-
tive associations with the concentrations of all HDL
subpopulations, but it was most pronounced with
small HDL (r = 0.40204, P = 0.0038) in the SLE group.
Also, anti-SSB showed an inverse relationship with
PON1 arylesterase activity (r = −0.33061, P = 0.019).
Disease activity, evaluated by the SLEDAI score,
showed a significant positive correlation with oxLDL
concentration (r = 0.34716, P = 0.0126). In the patients,
OxLDL levels correlated positively with SAA concentration
(r= 0.31279, P = 0.0344), ESR (r = 0.30226, P = 0.0368) and
hsCRP levels (r = 0.27253, P = 0.0582) concentrations and
oxLDL level was also associated with higher concen-
tration of ApoB (r = 0.31239, P = 0.0256). Further-
more, oxLDL level was related with decreased large
HDL ratio (r = −0.27118, P = 0.0595) and with in-
creased intermediate HDL ratio (r = 0.39379, P = 0.0042),
respectively; while showing a positive association with
fibrinogen concentration (r = 0.51245, P = 0.0001).
Table 2 HDL antioxidant enzyme activities and inflammatory markers
Characteristics SLE patients (n = 51) Controls (n = 49) P Value
PON1 paraoxonase activity (U/l) 118.01 ± 85.49 124.68 ± 102.96 0.857
PON1 arylesterase activity (U/l) 125.65 ± 26.87 148.35 ± 39.34 0.001
Paraoxonase activity/HDL 98.48 ± 69.92 76.20 ± 64.34 0.025
Arylesterase activity/HDL 109.05 ± 38.23 93.51 ± 33.30 0.036
Total HDL antioxidant capacity (%) 165.82 ± 58.28 217.71 ± 54.36 <0.001
OxLDL (mg/l) 3.55 ± 4.19 2.63 ± 3.22 0.291
HsCRP (mg/l) 5.02 ± 6.64 1.68 ± 1.88 0.002
ESR (mm/hour) 24.38 ± 17.96 7.90 ± 5.93 <0.001
IL-6 (ng/l) 0.54 (0–3.25) 0 (0–0.17) 0.002
SAA (ug/l) 19017.07 ± 25899.25 2666.05 ± 2301.11 <0.001
MCP-1 (ng/l) 473.24 (342.72-599.16) 309.72 (242.91-353.86) <0.001
SAA/HDL (ug/mmol) 18217.14 ± 29453.17 1692.24 ± 1459.34 <0.001
ESR erythrocyte sedimentation rate; HDL high-density lipoprotein; hsCRP high-sensitivity C-reactive protein; IL-6 interleukin-6; MCP-1 monocyte chemoattractant
protein-1; ox-LDL oxidized low-density lipoprotein; PON1 paraoxonase-1; SAA serum amyloid A
Statistically significant differences are marked in bold






Large HDL (mg/dl)a 18.37 ± 9.91 23.88 ± 10.33 0.012
Intermediate HDL (mg/dl)b 22.98 ± 6.48 32.15 ± 6.77 <0.001
Small HDL (mg/dl)c 6.51 ± 2.47 10.08 ± 3.53 <0.001
Small HDL-Large HDL ratio 0.41 ± 0.19 0.53 ± 0.41 0.077
Large HDL (%)a 36.57 ± 7.27 34.79 ± 8.02 0.268
Intermediate HDL (%)b 49.32 ± 5.42 49.50 ± 4.78 0.869
Small HDL (%)c 14.08 ± 3.94 15.69 ± 5.63 0.114
asum of HDL1, HDL2 and HDL3
bsum of HDL4, HDL5, HDL6 and HDL7
csum of HDL8, HDL9, and HDL10
Statistically significant differences are marked in bold
Fig. 1 Correlation of total HDL antioxidant capacity and PON1
arylesterase activity in the SLE group
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To test whether the associations detected in the
univariate analyses were independent of other laboratory
parameters, we carried out a multiple regression analysis
with total HDL antioxidant activity as the dependent
variable. The model included IL-6, hsCRP, MCP-1, SAA,
ESR and PON1 arylesterase activity. Total HDL antioxi-
dant activity turned out to be best predicted by the
PON1 arylesterase activity (p < 0.05, beta = 0.348) and
ESR (p < 0.01, beta = 0.61).
Discussion
Characterized by the SLEDAI score, our young SLE
cohort had a relatively high disease activity. Therefore, it
is not surprising that their basic lipoprotein profile
showed the typical “lupus pattern” [3, 4], featured by
elevated triglyceride and decreased HDL-C levels with-
out significant changes in total and LDL-C concentra-
tions. The concentration of ApoA1, which is the major
apolipoprotein of HDL, was also significantly decreased
in patients. Since intact function of ApoA1 is required
to the activation of ABCA1-dependent reverse choles-
terol transport and also to LCAT and PON1 enzyme
activation, decreased concentration or altered structure
of ApoA1 may lead to deficient HDL function [6, 27].
Despite the LDL levels being similar in our study groups,
ApoB concentration was higher in our lupus patients
compared to healthy subjects. Previously, increased
ApoB level was found to be associated to larger plaque
burden and larger presence of non-calcified plaques in
patients with ischemic heart disease [28]. In a previous
study on 87 SLE patients with inactive disease, ApoB
concentration was shown to be independently associated
with pulse wave velocity [29]. Deposition of ApoB within
the arterial wall, which is one of the initiating steps of
atherosclerosis, was detected in coronary plaques by
fluorescent microscopy [30].
Using our method of hemin-induced LDL oxidation,
we determined the specific antioxidant activity of HDL
in the study groups that both were characterized by
unaltered total cholesterol concentrations. HDL pro-
tected test LDL from oxidation, lengthening the time
period until the LDL oxidation reached its maximum
reaction velocity. None of the examined HDLs were
found to be “proinflammatory” according to our antioxi-
dant activity results. Surprisingly, specific HDL antioxi-
dant capacity was significantly elevated in patients;
while, at the same time, total HDL antioxidant capacity
was appreciably decreased in these individuals. Our data
might indicate altered RCT of the patients that provides
less cholesterol content, thus leading to increased
protein/cholesterol ratio in the HDL particles. We sup-
pose that higher enzyme concentration in the reaction
mixture results in enhanced antioxidant activity, although
not necessarily providing greater antioxidant protection.
Our findings differ from those reported by McMahon
et al. [17]. They detected the presence of proinflamma-
tory HDL in 44.7 % of their SLE cohort compared to the
4.1 % observed in the control group. In another study
from this research group, the overall frequency of piHDL
was 48.2 % among SLE patients; while 86.7 % of the
patients with carotid plaque carried piHDL contrary to
40.7 % of those without plaque [18]. The different study
Fig. 2 Correlation of total HDL antioxidant capacity and ESR in
SLE patients
Table 4 Correlations between markers of oxidative stress and inflammation in SLE patients
HDL-C total HDL antioxidant capacity
r P r P
PON1 arylesterase activity 0.378 <0.01 0.425 <0.01
PON1 paraoxonase activity 0.289 <0.05 0.290 <0.05
ESR −0.489 <0.0001 −0.419 <0.01
hsCRP −0.314 <0.01 −0.347 <0.001
IL-6 −0.489 <0.0001 −0.500 <0.0001
MCP-1 −0.467 <0.0001 −0.413 <0.0001
SAA −0.288 <0.01 −0.283 <0.01
ESR erythrocyte sedimentation rate; HDL high-density lipoprotein; hsCRP high-sensitivity C-reactive protein; IL-6 interleukin-6; MCP-1 monocyte chemoattractant
protein-1; PON1 paraoxonase-1; SAA serum amyloid A
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populations and methods applied in these studies may
explain the conflicting results. Their patients had signifi-
cantly decreased LDL-C, but similar TC, HDL-C and
TG concentrations than controls; while our group of
SLE subjects displayed diminished HDL-C and elevated
TG levels. Additionally, McMahon et al. used an end-
point measurement in contrast to our kinetic reaction
and the utilized pro-oxidants were also different. Although
piHDL was not detected in our study, total HDL anti-
oxidant activity of the lupus patients were significantly
decreased and it turned out to be best predicted by
PON1 arylesterase activity and ESR. These findings
highlight the role of the PON1 enzyme and the inflam-
matory processes in the regulation of the HDL antioxi-
dant status in SLE.
In a previous study by Kiss et al., decreased PON1
paraoxonase activity was found in SLE patients, while
PON1 arylesterase remained unaltered [10]. Similarly to
their results, we could not find significant differences
between patients and controls regarding PON1 pheno-
type distribution; and none of our study participants had
the high activity BB phenotype.
HDL maturation is a complex process followed by
structural and functional changes that are reflected by
the HDL subfraction distribution. The different subsets
of the lipoprotein particles carry various enzymes
and structural proteins that alter their function.
Small dense HDL particles are the main carriers of
the antioxidant enzymes including PON1, and they
are also important lipid acceptors during RCT.
Examining HDL subpopulations in both study
groups, they were measured to be equally diminished
in the SLE patients and correlated both with de-
creased HDL antioxidant activity and lower PON1
arylesterase activity.
Conclusion
In conclusion, total HDL antioxidant capacity was
severely diminished in SLE patients compared to con-
trols. The subsequent analyses of HDL subpopulations
revealed equally decreased HDL subfractions, while we
could not detect the presence of proinflammatory HDL
in the SLE subjects. Small HDL concentration and HDL
antioxidant capacity showed positive correlations with
PON1 arylesterase activity and inverse relationships with
inflammatory markers (MCP-1, IL-6, hsCRP), and
disease activity (SLEDAI). ESR and PON1 arylesterase
activity were independent predictors of total HDL antioxi-
dant activity. Due to the systemic inflammation in SLE,
altered composition and antioxidant activity of HDL may
diminish its anti-atherogenic effect and therefore may
contribute to the increased cardiovascular risk of SLE
patients. Negative correlations between HDL antioxidant
capacity and activity markers including ESR and immune
complex level highlight the role of disease activity in
decreased protection against atherogenesis in SLE.
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